Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Toripalimab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer

NCT07307456 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT07307456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07307456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Single-center Clinical Study Evaluating the Efficacy and Safety of Toripalimab Combined With BCG Perfusion as an Adjuvant Treatment After TURBT in High-risk/Very High-risk Non-muscle-invasive Bladder Cancer
Lead sponsor
Changhai Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 8, 2025
Completion date
December 8, 2028
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer